RxDoctor Payments Data

Kathi McCree, MD

Family Medicine · Webster, TXNPI 1497749816

Payments from drug & device makers

$1,945in general payments, 2019–2025

Across 100 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$371
  • AbbVie$308
  • Amgen$183
  • Eisai Inc.$102
  • Antares Pharma, Inc.$99
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$98
  • plus $784 from 25 others

What the payments were for

  • Food & beverage$1,945100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,945 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$43,461
Medicare patients
108
Services billed
517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban25$26,154
TrulicityDulaglutide20$18,273
MyrbetriqMirabegron17$18,210
Repatha SureclickEvolocumab18$12,149
Rosuvastatin Calcium199$3,289
SynthroidLevothyroxine Sodium29$2,061
Levothyroxine Sodium148$1,663
Memantine Hcl33$1,320
Desvenlafaxine Succinate ErDesvenlafaxine Succinate26$1,317
Metoprolol Succinate58$1,035
Escitalopram Oxalate47$908
Famotidine31$747
Losartan Potassium66$702
Albuterol Sulfate HfaAlbuterol Sulfate33$698
Ropinirole Hcl26$621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$71$26,15425 claims
Lilly USA, LLCTrulicity$51$18,27320 claims
Astellas Pharma US IncMyrbetriq$17$18,21017 claims
AbbVieSynthroid$308$2,06129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →